# OnCo record idea-reg-alpha-emitter-portfolio (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-reg-alpha-emitter-portfolio/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-reg-alpha-emitter-portfolio" ;
  schema:name "Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211"@en ;
  schema:description "Almost every alpha cancer therapy in development relies on one scarce isotope. Developing several alternatives at once would stop the whole field waiting on a single supply chain."@en ;
  schema:url <https://onco.cc/ideas/idea-reg-alpha-emitter-portfolio/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2018.0977> ;
  onco:technologies <https://onco.cc/technologies/targeted-alpha-therapy/> ;
  onco:companies <https://onco.cc/companies/orano-med/>, <https://onco.cc/companies/perspective-therapeutics/> ;
  onco:terms <https://onco.cc/terms/alpha-vs-beta/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-hernandez-jama-oncol/> .